{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:05:28Z","timestamp":1782277528698,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019871","name":"Castle Biosciences, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019871","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-024-03640-x","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T06:02:55Z","timestamp":1735884175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma"],"prefix":"10.1186","volume":"23","author":[{"given":"J. Michael","family":"Guenther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cripe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley P.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph I.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hamner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"3640_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.2055","author":"Multicenter Selective Lymphadenectomy Trials Study Group","year":"2022","unstructured":"Multicenter Selective Lymphadenectomy Trials Study Group. Therapeutic Value of Sentinel Lymph Node Biopsy in patients with melanoma: a Randomized Clinical Trial. JAMA Surg. 2022. https:\/\/doi.org\/10.1001\/jamasurg.2022.2055.","journal-title":"JAMA Surg"},{"key":"3640_CR2","doi-asserted-by":"publisher","first-page":"45671","DOI":"10.18632\/oncotarget.10140","volume":"7","author":"J Chen","year":"2016","unstructured":"Chen J, et al. Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: a retrospective study of surveillance, epidemiology, and end-result population-based data. Oncotarget. 2016;7:45671\u20137.","journal-title":"Oncotarget"},{"key":"3640_CR3","doi-asserted-by":"crossref","unstructured":"Fayne RA, Macedo FI, Rodgers SE, M\u00f6ller MG. Evolving management of positive regional lymph nodes in melanoma: past, present and future directions. Oncol Rev 13, (2019).","DOI":"10.4081\/oncol.2019.433"},{"key":"3640_CR4","doi-asserted-by":"publisher","first-page":"e236356","DOI":"10.1001\/jamanetworkopen.2023.6356","volume":"6","author":"JR Miller","year":"2023","unstructured":"Miller JR, et al. Improving selection for Sentinel Lymph Node Biopsy among patients with Melanoma. JAMA Netw Open. 2023;6:e236356.","journal-title":"JAMA Netw Open"},{"key":"3640_CR5","doi-asserted-by":"publisher","unstructured":"Whitman ED, et al. Integrating 31-Gene expression profiling with clinicopathologic features to optimize cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction. JCO Precision Oncol. 2021;1466\u201379. https:\/\/doi.org\/10.1200\/PO.21.00162.","DOI":"10.1200\/PO.21.00162"},{"key":"3640_CR6","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jaad.2022.06.1202","volume":"87","author":"A Jarell","year":"2022","unstructured":"Jarell A, et al. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. J Am Acad Dermatol. 2022;87:1312\u201320.","journal-title":"J Am Acad Dermatol"},{"key":"3640_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/PO.20.00119","volume":"5","author":"EC Hsueh","year":"2021","unstructured":"Hsueh EC, et al. Long-term outcomes in a Multicenter, prospective cohort evaluating the Prognostic 31-Gene expression Profile for cutaneous melanoma. JCO Precision Oncol. 2021;5:589\u2013601.","journal-title":"JCO Precision Oncol"},{"key":"3640_CR8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/fon-2018-0912","volume":"15","author":"JT Vetto","year":"2019","unstructured":"Vetto JT, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1\u2013T2 melanoma using gene expression profiling. Future Oncol. 2019;15:1207\u201317.","journal-title":"Future Oncol"},{"key":"3640_CR9","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.amjsurg.2021.03.028","volume":"221","author":"SP Arnot","year":"2021","unstructured":"Arnot SP, et al. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. Am J Surg. 2021;221:1195\u20139.","journal-title":"Am J Surg"},{"key":"3640_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/03007995.2023.2165813","volume":"39","author":"M Yamamoto","year":"2023","unstructured":"Yamamoto M, et al. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study. Curr Med Res Opin. 2023;39:417\u201323.","journal-title":"Curr Med Res Opin"},{"key":"3640_CR11","doi-asserted-by":"publisher","first-page":"474","DOI":"10.25251\/skin.6.6.4","volume":"6","author":"A Glazer","year":"2022","unstructured":"Glazer A, Tassavor M, Portela D, Soleymani T. The Integrated 31-Gene expression Profile Test (i31-GEP) for cutaneous melanoma outperforms the CP-GEP at identifying patients who can Forego Sentinel Lymph Node Biopsy when applying NCCN guidelines. J Skin. 2022;6:474\u201381.","journal-title":"J Skin"},{"key":"3640_CR12","doi-asserted-by":"crossref","unstructured":"Guenther JM et al. Patients who forego sentinel lymph node biopsy after 31-GEP testing are not harmed: a prospective, multicenter analysis. EJC Skin Cancer 2, (2024).","DOI":"10.1016\/j.ejcskn.2024.100175"},{"key":"3640_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, et al. Final Trial Report of Sentinel-Node Biopsy versus nodal Observation in Melanoma. N Engl J Med. 2014;370:599\u2013609.","journal-title":"N Engl J Med"},{"key":"3640_CR14","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.3390\/jcm10245878","volume":"10","author":"A Tejera-Vaquerizo","year":"2021","unstructured":"Tejera-Vaquerizo A, et al. Sentinel Lymph Node Biopsy vs. Observation in Thin Melanoma: a Multicenter Propensity score matching study. J Clin Med. 2021;10:5878.","journal-title":"J Clin Med"},{"key":"3640_CR15","doi-asserted-by":"crossref","unstructured":"Helvind NM et al. Stage-specific risk of recurrence and death from Melanoma in Denmark, 2008\u20132021: a National Observational Cohort Study of 25 720 patients with Stage IA to IV Melanoma. JAMA Dermatology (2023).","DOI":"10.1001\/jamadermatol.2023.3256"},{"key":"3640_CR16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-11761-4","author":"MD Moncrieff","year":"2022","unstructured":"Moncrieff MD, et al. Evaluation of the indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant systemic therapy: an International, Multicenter Study. Ann Surg Oncol. 2022. https:\/\/doi.org\/10.1245\/s10434-022-11761-4.","journal-title":"Ann Surg Oncol"},{"key":"3640_CR17","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1245\/s10434-023-13736-5","volume":"30","author":"CE Sharon","year":"2023","unstructured":"Sharon CE, et al. Impact of adjuvant immunotherapy on overall survival in a contemporary cohort of patients with Stage III Melanoma. Ann Surg Oncol. 2023;30:5329\u201332.","journal-title":"Ann Surg Oncol"},{"key":"3640_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ejso.2016.06.407","volume":"43","author":"JA Moody","year":"2017","unstructured":"Moody JA, Ali RF, Carbone AC, Singh S, Hardwicke JT. Complications of sentinel lymph node biopsy for melanoma \u2013 a systematic review of the literature. Eur J Surg Oncol. 2017;43:270\u20137.","journal-title":"Eur J Surg Oncol"},{"key":"3640_CR19","doi-asserted-by":"publisher","first-page":"5248","DOI":"10.1245\/s10434-020-08558-8","volume":"27","author":"Y Hu","year":"2020","unstructured":"Hu Y, et al. Sentinel Lymph Node Biopsy for T1b melanoma: balancing Prognostic Value and cost. Ann Surg Oncol. 2020;27:5248\u201356.","journal-title":"Ann Surg Oncol"},{"key":"3640_CR20","doi-asserted-by":"crossref","unstructured":"Zakria D et al. The health economic impact of the 31-gene expression profile test for treatment and surveillance management plans in patients with cutaneous melanoma. EJC Skin Cancer 2, (2024).","DOI":"10.1016\/j.ejcskn.2024.100109"},{"key":"3640_CR21","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00403-023-02613-6","volume":"315","author":"S Dhillon","year":"2023","unstructured":"Dhillon S, et al. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. Arch Dermatol Res. 2023;315:2295\u2013302.","journal-title":"Arch Dermatol Res"},{"key":"3640_CR22","doi-asserted-by":"publisher","first-page":"e2300044","DOI":"10.1200\/PO.23.00044","volume":"7","author":"CN Bailey","year":"2023","unstructured":"Bailey CN, et al. 31-Gene expression Profile Testing in Cutaneous Melanoma and Survival outcomes in a Population-based analysis: a SEER collaboration. JCO Precis Oncol. 2023;7:e2300044.","journal-title":"JCO Precis Oncol"},{"issue":"23","key":"3640_CR23","doi-asserted-by":"publisher","first-page":"01350","DOI":"10.1016\/j.jaad.2023.07.011","volume":"S0190\u20139622","author":"SC Freeman","year":"2023","unstructured":"Freeman SC, Munoz EP, Latour E, Lim JY, Yu W. External validation of the Melanoma Institute Australia Sentinel Node Metastasis Risk Prediction Tool using the National Cancer Database. J Am Acad Dermatol. 2023;S0190\u20139622(23):01350\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.011.","journal-title":"J Am Acad Dermatol"},{"key":"3640_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27231","author":"S Hosein","year":"2023","unstructured":"Hosein S, et al. Are the MIA and MSKCC nomograms useful in selecting patients with melanoma for sentinel lymph node biopsy? J Surg Oncol. 2023. https:\/\/doi.org\/10.1002\/jso.27231.","journal-title":"J Surg Oncol"},{"key":"3640_CR25","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14862-w","author":"S Maddineni","year":"2024","unstructured":"Maddineni S, et al. Validation of the Melanoma Institute of Australia\u2019s Sentinel Lymph Node Biopsy Risk Prediction Tool for cutaneous melanoma. Ann Surg Oncol. 2024. https:\/\/doi.org\/10.1245\/s10434-023-14862-w.","journal-title":"Ann Surg Oncol"},{"key":"3640_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/XCS.0000000000000886","volume":"238","author":"HM Drebin","year":"2024","unstructured":"Drebin HM, et al. Clinical Utility of Melanoma Sentinel Lymph Node Biopsy Nomograms. J Am Coll Surg. 2024;238:23\u201331.","journal-title":"J Am Coll Surg"},{"key":"3640_CR27","doi-asserted-by":"publisher","unstructured":"Bagge RO et al. Population-Based Validation of the MIA and MSKCC Tools for Predicting Sentinel Lymph Node Status. JAMA Surg e236904 (2024) https:\/\/doi.org\/10.1001\/jamasurg.2023.6904","DOI":"10.1001\/jamasurg.2023.6904"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03640-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03640-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03640-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T07:10:42Z","timestamp":1735888242000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03640-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3640"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03640-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was obtained from WCG-IRB and additionally at each participating institution where required by the institution. All participants provided informed consent at visit one.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BJM is an employee and options\/shareholder at Castle Biosciences. JMG, AW, and RS are on the speaker\u2019s bureau for Castle Biosciences. All other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}